Structure−Activity Relationship of 2-Oxoamide Inhibition of Group IVA Cytosolic Phospholipase A2and Group V Secreted Phospholipase A2
Citations Over TimeTop 10% of 2007 papers
Abstract
The Group IVA cytosolic phospholipase A2 (GIVA cPLA2) is a key provider of substrates for the production of eicosanoids and platelet-activating factor. We explored the structure-activity relationship of 2-oxoamide-based compounds and GIVA cPLA2 inhibition. The most potent inhibitors are derived from delta- and gamma-amino acid-based 2-oxoamides. The optimal side-chain moiety is a short nonpolar aliphatic chain. All of the newly developed 2-oxoamides as well as those previously described have now been tested with the human Group V secreted PLA2 (GV sPLA2) and the human Group VIA calcium-independent PLA2 (GVIA iPLA2). Only one 2-oxoamide compound had appreciable inhibition of GV sPLA2, and none of the potent GIVA cPLA2 inhibitors inhibited either GV sPLA2 or GVIA iPLA2. Two of these specific GIVA cPLA2 inhibitors were also found to have potent therapeutic effects in animal models of pain and inflammation at dosages well below the control nonsteroidal anti-inflammatory drugs.
Related Papers
- → Redistribution of 5-Lipoxygenase and Cytosolic Phospholipase A2 to the Nuclear Fraction upon Macrophage Activation(1993)180 cited
- → Translocation of phospholipase A2 from cytosol to membranes in rat brain induced by calcium ions(1990)123 cited
- → A novel type of phospholipase A2 inhibitor, thielocin A1.BETA., and mechanism of action.(1992)27 cited
- → Augmented expression of cytosolic phospholipase A2 during phenotypic transformation of cultured type II pneumocytes(1994)37 cited
- → Phospholipases A1 and A2 of rat liver plasma membranes; mechanism of action(1976)25 cited